Search

Your search keyword '"Tan, Wan Ling"' showing total 21 results
Start Over Author "Tan, Wan Ling" Search Limiters Peer Reviewed
21 results on '"Tan, Wan Ling"'

1. Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC

Author

Saw, Stephanie P.L., Low, Yi Fen, Lai, Gillianne G.Y., Chan, Landon L., Wong, Wesley K.Y., Tsui, Giselle, Chen, Olivia H., Seet, Amanda O.L., Tan, Wei Chong, Tan, Aaron C., Chan, Johan W.K., Teh, Yi Lin, Tan, Wan-Ling, Ng, Quan Sing, Ang, Mei-Kim, Kanesvaran, Ravindran, Lim, Darren W.T., Tan, Daniel S.W., Mok, Tony S.K., and Li, Molly S.C.

Published
2024
Full Text
View/download PDF

2. Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma

Author

Lim, Darren Wan-Teck, Kao, Hsiang-Fong, Suteja, Lisda, Li, Constance H., Quah, Hong Sheng, Tan, Daniel Shao-Weng, Tan, Sze-Huey, Tan, Eng-Huat, Tan, Wan-Ling, Lee, Justina Nadia, Wee, Felicia Yu-Ting, Jain, Amit, Goh, Boon-Cher, Chua, Melvin L. K., Liao, Bin-Chi, Ng, Quan Sing, Hong, Ruey-Long, Ang, Mei-Kim, Yeong, Joe Poh-Sheng, and Iyer, N. Gopalakrishna

Published
2023
Full Text
View/download PDF

3. PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer

Author

Saw, Stephanie P.L., Ng, Win Pin, Zhou, Siqin, Lai, Gillianne G.Y., Tan, Aaron C., Ang, Mei-Kim, Lim, Wan-Teck, Kanesvaran, Ravindran, Ng, Quan Sing, Jain, Amit, Tan, Wan Ling, Rajasekaran, Tanujaa, Chan, Johan W.K., Teh, Yi Lin, Pang, Mengyuan, Yeo, Jia-Chi, Takano, Angela, Ong, Boon-Hean, Tan, Eng-Huat, Tan, Sze Huey, Skanderup, Anders J., and Tan, Daniel S.W.

Published
2023
Full Text
View/download PDF

4. A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC

Author

Lai, Gillianne G.Y., Yeo, Jia Chi, Jain, Amit, Zhou, Siqin, Pang, Mengyuan, Alvarez, Jacob J.S., Sim, Ngak Leng, Tan, Aaron C., Suteja, Lisda, Lim, Tze Wei, Guo, Yu Amanda, Shen, Meixin, Saw, Stephanie P.L., Rohatgi, Neha, Yeong, Joe P.S., Takano, Angela, Lim, Kiat Hon, Gogna, Apoorva, Too, Chow Wei, Da Zhuang, Kun, Tan, Wan Ling, Kanesvaran, Ravindran, Ng, Quan Sing, Ang, Mei Kim, Rajasekaran, Tanujaa, Wang, Lanying, Toh, Chee Keong, Lim, Wan-Teck, Tam, Wai Leong, Tan, Sze Huey, Skanderup, Anders M.J., Tan, Eng-Huat, and Tan, Daniel S.W.

Published
2022
Full Text
View/download PDF

7. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis

Author

Tan, Aaron C., Lai, Gillianne G.Y., Tan, Gek San, Poon, Shou Yu, Doble, Brett, Lim, Tse Hui, Aung, Zaw Win, Takano, Angela, Tan, Wan Ling, Ang, Mei-Kim, Tan, Bien Soo, Devanand, Anantham, Too, Chow Wei, Gogna, Apoorva, Ong, Boon-Hean, Koh, Tina P.T., Kanesvaran, Ravindran, Ng, Quan Sing, Jain, Amit, Rajasekaran, Tanujaa, Lim, Alvin S.T., Lim, Wan Teck, Toh, Chee Keong, Tan, Eng-Huat, Lim, Tony Kiat Hon, and Tan, Daniel S.W.

Published
2020
Full Text
View/download PDF

12. Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLC.

Author

Tan, Aaron C., Seet, Amanda O.L., Lai, Gillianne G.Y., Lim, Tse Hui, Lim, Alvin S.T., Tan, Gek San, Takano, Angela, Tai, David W.M., Tan, Tira J.Y., Lam, Justina Y.C., Ng, Matthew C.H., Tan, Wan Ling, Ang, Mei-Kim, Kanesvaran, Ravindran, Ng, Quan Sing, Jain, Amit, Rajasekaran, Tanujaa, Lim, Wan-Teck, Tan, Eng-Huat, and Lim, Tony Kiat Hon

Published
2020
Full Text
View/download PDF

13. From presentation to paper: Gender disparities in oncological research.

Author

Dijksterhuis, Willemieke P.M., Stroes, Charlotte I., Tan, Wan‐Ling, Ithimakin, Suthinee, Calles, Antonio, Oijen, Martijn G.H., Verhoeven, Rob H.A., Barriuso, Jorge, Oosting, Sjoukje F., Ivankovic, Daniela Kolarevic, Furness, Andrew J.S., Bozovic‐Spasojevic, Ivana, Gomez‐Roca, Carlos, and Laarhoven, Hanneke W.M.

Subjects
MANN Whitney U Test, GENDER, TREND analysis, EDUCATORS
Abstract

Gender disparities in scientific publications have been identified in oncological research. Oral research presentations at major conferences enhance visibility of presenters. The share of women presenting at such podia is unknown. We aim to identify gender‐based differences in contributions to presentations at two major oncological conferences. Abstracts presented at plenary sessions of the American Society of Clinical Oncology (ASCO) Annual Meetings and European Society for Medical Oncology (ESMO) Congresses were collected. Trend analyses were used to analyze female contribution over time. The association between presenter's sex, study outcome (positive/negative) and journals' impact factors (IFs) of subsequently published papers was assessed using Chi‐square and Mann–Whitney U tests. Of 166 consecutive abstracts presented at ASCO in 2011–2018 (n = 34) and ESMO in 2008–2018 (n = 132), 21% had female presenters, all originating from Northern America (n = 17) or Europe (n = 18). The distribution of presenter's sex was similar over time (p = 0.70). Of 2,425 contributing authors to these presented abstracts, 28% were women. The proportion of female abstract authors increased over time (p < 0.05) and was higher in abstracts with female (34%) compared to male presenters (26%; p < 0.01). Presenter's sex was not associated with study outcome (p = 0.82). Median journals' IFs were lower in papers with a female first author (p < 0.05). In conclusion, there is a clear gender disparity in research presentations at two major oncological conferences, with 28% of authors and 21% of presenters of these studies being female. Lack of visibility of female presenters could impair acknowledgement for their research, opportunities in their academic career and even hamper heterogeneity in research. What's new? Presenting one's research at a conference is a great way to get your name and ideas heard within the professional community. In this study, the authors investigated how often women served as presenters at plenary sessions of ASCO Annual Meetings and ESMO Congresses. Looking through 166 abstracts over a period of 8 years, they found that 21% had female presenters, while 28% of study authors were female. Lack of visibility for female researchers at conferences can slow their career progress, and greater representation should be encouraged. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

14. Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.

Author

Lai, Gillianne G.Y., Lim, Tse Hui, Lim, John, Liew, Perry J.R., Kwang, Xue Lin, Nahar, Rahul, Aung, Zaw Win, Takano, Angela, Lee, Yin Yeng, Lau, Dawn P.X., Tan, Gek San, Tan, Sze Huey, Tan, Wan Ling, Ang, Mei-Kim, Toh, Chee Keong, Tan, Bien Soo, Devanand, Anantham, Too, Chow Wei, Gogna, Apoorva, and Ong, Boon Hean

Published
2019
Full Text
View/download PDF

15. Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.

Author

Tan, Wan-Ling, Ng, Quan Sing, Lim, Cindy, Tan, Eng Huat, Toh, Chee Keong, Ang, Mei-Kim, Kanesvaran, Ravindran, Jain, Amit, Tan, Daniel S. W., and Lim, Darren Wan-Teck

Subjects
*BRAIN metastasis, *EPIDERMAL growth factor receptors, *PROTEIN-tyrosine kinases, *NON-small-cell lung carcinoma, *CENTRAL nervous system cancer, *ANTINEOPLASTIC agents, *BRAIN tumors, *CELL receptors, *DOSE-effect relationship in pharmacology, *LUNG cancer, *LUNG tumors, *GENETIC mutation, *RESEARCH funding, *TREATMENT effectiveness, *RETROSPECTIVE studies
Abstract

Background: Afatinib is an oral irreversible epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) indicated in first-line treatment of advanced EGFR-mutant (EGFRm+) non-small cell lung cancer (NSCLC). Dose dependent side effects can limit drug exposure, which may impact on extracranial and central nervous system (CNS) disease control.Methods: We performed a retrospective study of 125 patients diagnosed with advanced EGFRm+ NSCLC treated with first-line afatinib at a tertiary Asian cancer center, exploring clinicopathological factors that may influence survival outcomes. Median progression free survival (PFS) was estimated using the Kaplan-Meier method. Comparison of PFS between subgroups of patients was done using log-rank tests and Cox proportional hazards models.Results: Out of 125 patients, 62 (49.6%) started on 40 mg once daily (OD) afatinib, 61 (48.8%) on 30 mg OD and 1 (0.8%) on 20 mg OD. After median follow-up of 13.8 months from afatinib initiation, the observed response rate was 70.4% and median PFS 11.9 months (95% CI 10.3-19.3). 42 (33.6%) patients had baseline brain metastases (BM) and PFS of those who started on 40 mg OD (n = 17) vs. 30 mg OD (n = 25) was 13.3 months vs. 5.3 months (HR 0.39, 95% CI 0.15-0.99). BM+ patients who started on 40 mg had similar PFS to patients with no BM (13.3 months vs. 15.0 months; HR 0.79, 95% CI 0.34-1.80).Conclusion: In patients with advanced EGFRm+ NSCLC with BM+, initiating patients on afatinib 40 mg OD was associated with improved PFS compared to 30 mg OD, underscoring the potential importance of dose intensity in control of CNS disease. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

18. Comparison of hepatocellular carcinoma in Eastern versus Western populations.

Author

Choo, Su Pin, Tan, Wan Ling, Goh, Brian K. P., Tai, Wai Meng, and Zhu, Andrew X.

Subjects
*LIVER cancer, *TREATMENT effectiveness, *CLINICAL trials, *ETIOLOGY of diseases, *CANCER-related mortality
Abstract

Hepatocellular carcinoma (HCC) is a heterogeneous disease that remains highly prevalent in many Asian countries and is the second most common cause of cancer-related mortality worldwide. Significant differences exist between Eastern and Western populations on many key aspects of HCC, contributing to the potential different treatment outcomes and challenges of clinical trial design and data interpretation. In this review, the authors compare HCC in Asia versus the West and highlight 1) differences in terms of epidemiology and trends and their correlation with etiology, 2) differences in genetics and how they relate to underlying etiology, 3) differences in treatment approaches based on existing guidelines and consensus statements, and 4) differences in clinical outcomes for Asian versus non-Asian patients with HCC in clinical trials and the implications for future clinical trial design. Cancer 2016;122:3430-3446. © 2016 American Cancer Society. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

20. Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor–Positive Non–Small Cell Lung Cancer.

Author

Saw, Stephanie P. L., Zhou, Siqin, Chen, Jianbin, Lai, Gillianne, Ang, Mei-Kim, Chua, Kevin, Kanesvaran, Ravindran, Ng, Quan Sing, Jain, Amit, Tan, Wan Ling, Rajasekaran, Tanujaa, Lim, Darren W. T., Tan, Aaron, Fong, Kam Weng, Takano, Angela, Cheng, Xin Ming, Lim, Kiat Hon, Koh, Tina, Ong, Boon-Hean, and Tan, Eng Huat

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results